Fred Knoll

Knoll Capital Management LP is an independent hedge fund manager headquartered in New York City. In 1987, Fred Knoll founded the firm and used the funds from his family trust.

GVI Security Solutions, Inc. was a provider of video surveillance security solutions to the homeland security, institutional and commercial market segments. The company offered a full suite of video surveillance and integrated security solutions that enable intelligent video surveillance. GVI Security Solutions was founded in August 1996 and was headquartered in Carrollton, Texas.

General American Investors Co., Inc. is a closed-end mutual fund, which engages in managing a global portfolio of investments, consisting mainly of U.S. securities, and also some international and private securities. Its objective is long-term capital appreciation through investment in companies with above average growth potential. The company was founded in 1927 and is headquartered in New York, NY.

Data General Corp. designs and makes open computer systems including servers and mass storage products. The company was founded in 1968 and is headquartered in Westborough, MA

Founded in 2004 by Fred Knoll, KOM Capital Management LLC is hedge fund manager located in New York City. The firm is affiliated with Knoll Capital Management LP, a New York City-based family office firm that was founded in 1987. KOM Capital Management manages the Knoll Fund

AtheroNova, Inc. operates as biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. The company was founded by Giorgio Zadini and Filiberto Zadini in 1997 and is headquartered in Irvine, CA.

Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ.